Haqq Jonathan, Howells Lynne M, Garcea Giuseppe, Metcalfe Matthew S, Steward Will P, Dennison Ashley R
Department of Hepatobiliary and Pancreatic Surgery & Cancer Studies and Molecular Medicine Group, University Hospitals of Leicester & University of Leicester, Leicester LE5 4PW, United Kingdom.
Department of Hepatobiliary and Pancreatic Surgery & Cancer Studies and Molecular Medicine Group, University Hospitals of Leicester & University of Leicester, Leicester LE5 4PW, United Kingdom.
Eur J Cancer. 2014 Oct;50(15):2570-82. doi: 10.1016/j.ejca.2014.06.021. Epub 2014 Aug 1.
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease with a very poor prognosis. To date patient outcomes have not improved principally due to the limited number of patients suitable for surgical resections and the radiation and chemotherapy resistance of these tumours. In the last decade, a failure of conventional therapies has forced researchers to re-examine the environment of PDAC. The tumour environment has been demonstrated to consist of an abundance of stroma containing many cells but predominantly pancreatic stellate cells (PSCs). Recent research has focused on understanding the interaction between PSCs and PDAC cells in vitro and in vivo. It is believed that the interaction between these cells is responsible for supporting tumour growth, invasion and metastasis and creating the barrier to delivery of chemotherapeutics. Novel approaches which focus on the interactions between PDAC and PSCs which sustain the tumour microenvironment may achieve significant patient benefits. This manuscript reviews the current evidence regarding PSCs, their interaction with PDAC cells and the potential implication this may have for future therapies.
A PubMed search was carried out for the terms 'pancreas cancer' OR 'pancreatic cancer', AND 'pancreatic stellate cells', NOT 'hepatic stellate cells'. All studies were screened and assessed for their eligibility and manuscripts exploring the relationship between PSCs and PDAC were included. The studies were subdivided into in vitro and in vivo groups.
One hundred and sixty-six manuscripts were identified and reduced to seventy-three in vitro and in vivo studies for review. The manuscripts showed that PDAC cells and PSCs interact with each other to enhance proliferation, reduce apoptosis and increase migration and invasion of cancer cells. The pathways through which they facilitate these actions provide potential targets for future novel therapies.
There is accumulating evidence supporting the multiple roles of PSCs in establishing the tumour microenvironment and supporting the survival of PDAC. To further validate these findings there is a need for greater use of physiologically relevant models of pancreatic cancer in vitro such as three dimensional co-cultures and the use of orthotopic and genetically engineered murine (GEM) models in vivo.
胰腺导管腺癌(PDAC)是一种恶性程度很高的疾病,预后极差。迄今为止,患者的治疗效果并未得到显著改善,主要原因是适合手术切除的患者数量有限,以及这些肿瘤对放疗和化疗具有抗性。在过去十年中,传统疗法的失败促使研究人员重新审视PDAC的肿瘤环境。肿瘤环境已被证明由大量基质组成,其中包含许多细胞,但主要是胰腺星状细胞(PSC)。最近的研究集中在了解PSC与PDAC细胞在体外和体内的相互作用。据信,这些细胞之间的相互作用有助于肿瘤生长、侵袭和转移,并形成化疗药物递送的障碍。专注于PDAC与维持肿瘤微环境的PSC之间相互作用的新方法可能会给患者带来显著益处。本文综述了关于PSC的现有证据、它们与PDAC细胞的相互作用以及这可能对未来治疗产生的潜在影响。
在PubMed上搜索“胰腺癌”或“胰腺导管腺癌”以及“胰腺星状细胞”,不包括“肝星状细胞”。对所有研究进行筛选和评估以确定其是否符合条件,纳入探索PSC与PDAC之间关系的手稿。这些研究被分为体外和体内两组。
共识别出166篇手稿,筛选后保留73篇体外和体内研究进行综述。这些手稿表明,PDAC细胞与PSC相互作用,以增强癌细胞的增殖、减少凋亡并增加其迁移和侵袭。它们促进这些作用的途径为未来的新疗法提供了潜在靶点。
越来越多的证据支持PSC在建立肿瘤微环境和支持PDAC存活方面的多重作用。为了进一步验证这些发现,需要更多地使用体外生理相关的胰腺癌模型,如三维共培养,以及体内原位和基因工程小鼠(GEM)模型。